Hikma's Epinephrine ANDA220562 Receives Abbreviated Approval from FDA
Hikma's application ANDA220562 for epinephrine has received Abbreviated Approval (AP) from the FDA.
Asset / Drug
Drug and asset intelligence for Epinephrine with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.